Summary
Medtronic plc reported solid performance in its fiscal year 2024, with total net sales increasing by 4% to $32.36 billion. The company's growth was driven by its Neuroscience Portfolio (up 5%), Medical Surgical Portfolio (up 5%), and particularly its Diabetes Operating Unit (up 10%). Key product areas showing strength include Cardiac Rhythm & Heart Failure, Coronary & Peripheral Vascular, Cranial & Spinal Technologies, and Surgical & Endoscopy divisions. Financially, Medtronic demonstrated strong operating cash flow and free cash flow, with free cash flow reaching $5.2 billion. The company also returned value to shareholders through dividends and share repurchases, authorizing an additional $5.0 billion for repurchases. Despite global economic uncertainties and some product-specific challenges, Medtronic's diversified business segments and international presence contributed to resilient growth. The company continues to invest in innovation, with R&D expenses remaining consistent year-over-year.
Financial Highlights
55 data points| Revenue | $32.36B |
| Cost of Revenue | $11.22B |
| Gross Profit | $21.15B |
| SG&A Expenses | $10.74B |
| Operating Income | $5.14B |
| Interest Expense | $719.00M |
| Net Income | $3.68B |
| EPS (Basic) | $2.77 |
| EPS (Diluted) | $2.76 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.33B |
Key Highlights
- 1Total net sales increased by 4% to $32.36 billion for fiscal year 2024.
- 2Neuroscience, Medical Surgical, and Diabetes segments showed robust growth of 5%, 5%, and 10% respectively.
- 3Free cash flow was strong at $5.2 billion, indicating healthy operational performance and cash generation.
- 4Medtronic authorized an additional $5.0 billion for share repurchases, demonstrating commitment to shareholder returns.
- 5Key product launches and adoption of new technologies, such as the PulseSelect PFA system and the Aurora EV-ICD system, are driving growth in the Cardiovascular segment.
- 6The company is strategically exiting certain product lines, such as ventilators, to focus resources on core growth areas.
- 7R&D expenses remained stable at $2.7 billion, underscoring continued investment in innovation across its portfolios.